In fiscal year 2025, MYUNGMOON PHARM (017180) reported revenue of 195.2 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|
| 2025 | 195.2 billion KRW | 6.8 billion KRW | 1.4 billion KRW | [source] |
| 2024 | 186.4 billion KRW | 1.9 billion KRW | -3.8 billion KRW | [source] |
| 2023 | 169.6 billion KRW | 964 million KRW | -4.9 billion KRW | [source] |
| 2022 | 152.1 billion KRW | 6.4 billion KRW | 8.0 billion KRW | [source] |
| 2021 | 137.8 billion KRW | -5.9 billion KRW | -6.8 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|
| 2025 | 219.1 billion KRW | 120.8 billion KRW | 98.3 billion KRW | [source] |
| 2024 | 206.5 billion KRW | 110.1 billion KRW | 96.4 billion KRW | [source] |
| 2023 | 187.9 billion KRW | 104.5 billion KRW | 83.5 billion KRW | [source] |
| 2022 | 181.0 billion KRW | 91.4 billion KRW | 89.5 billion KRW | [source] |
| 2021 | 176.2 billion KRW | 95.9 billion KRW | 80.3 billion KRW | [source] |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|
| 2025 | -1.7 billion KRW | -7.2 billion KRW | 10.3 billion KRW | [source] |
| 2024 | -1.3 billion KRW | 968 million KRW | -3.2 billion KRW | [source] |
| 2023 | -5.2 billion KRW | 1.8 billion KRW | 6.5 billion KRW | [source] |
| 2022 | 8.0 billion KRW | — | — | [source] |
| 2021 | 4.7 billion KRW | — | — | [source] |
Cash flow figures for the relevant year were not collected.
